There are some exciting potential treatments for ovarian cancer currently being tested in clinical trials. |
Called antiangiogenic agents, they are antibodies that inhibit the growth of blood vessels within cancerous tumours, preventing or slowing their growth.
‘Early indications evaluating the antiangiogenic agent Bevacizumab in ovarian cancer look encouraging,’ said Professor Ledermann. ‘Also, Cancer Research UK is funding a trial using Intraperitoneal Chemotherapy, where the drugs are channelled directly into the abdominal cavity. This approach may have a more direct and hard-hitting effect on the ovarian cancer.’